Author:
Hyung Jaewon,Kim Bumjun,Yoo Changhoon,Kim Kyo-pyo,Jeong Jae Ho,Chang Heung-Moon,Ryoo Baek-Yeol
Funder
National Research Foundation of Korea
Ministry of Science, ICT and Future Planning
Publisher
Korean Cancer Association
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial;Journal of Clinical Oncology;2024-08-05
2. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study;The Lancet Gastroenterology & Hepatology;2024-08
3. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT);European Journal of Cancer;2024-05
4. PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder cancer: A retrospective comparative study;2024-04-02
5. Defining the Mode of Action of Cisplatin Combined with a Phosphoramidate Modification of Gemcitabine;2024